Drug Profile


Alternative Names: AFN 1720; AFN-1252-prodrug; Debio 1450; Debio-1452-prodrug

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Affinium Pharmaceuticals
  • Developer Debiopharm Group
  • Class Anti-infectives; Benzofurans; Naphthyridines; Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteomyelitis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Skin and soft tissue infections
  • Phase I Bone and joint infections
  • No development reported Staphylococcal infections

Most Recent Events

  • 28 Jul 2017 Chemical structure information added
  • 07 Jul 2017 No development reported - Phase-I for Staphylococcal infections (In volunteers) in USA (PO; Tablet, Liquid, Suspension)
  • 14 Jun 2017 Debiopharm initiates a phase I drug-drug interaction trial in Healthy volunteers in United Kingdom (NCT03209648)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top